FTP-198 / Haisco - LARVOL DELTA

Autotaxin inhibitors: an updated patent review (2021-present). (PubMed, Expert Opin Ther Pat) - "Currently, beyond the Phase II candidates PAT409 and HW021199, ATX inhibitors FTP-198 and HNC1058 have entered Phase I clinical trials for pulmonary fibrosis, while IOA-289 and HNC664 have advanced to clinical studies for solid tumors, underscoring the immense therapeutic potential of ATX. Although the identification of type V and VI ATX inhibitors has broadened the design landscape, most emerging entities since 2020 remain analogs of GLPG1690 and PAT409, presumably being attributed to the unavailable data of most clinical candidates, and despite the absence of approved drugs, the continued evolution of drug design strategies and application of novel technologies would further facilitate the discovery of ATX candidates, ultimately offering more therapeutic options for patients."

Journal • Review • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective autotaxin inhibitor, in healthy subjects: a phase I randomized placebo-controlled trial. (PubMed, Eur J Pharm Sci) - "Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198 support further subsequent clinical development of FTP -198 in IPF patients."

Clinical • Journal • P1 data • PK/PD data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Recruiting ➔ Completed

Trial completion

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers (clinicaltrials.gov) - P1; N=75; Completed; Sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd; Recruiting ➔ Completed

Clinical • Trial completion

Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial

Hasko's innovative drug for idiopathic pulmonary fibrosis approved for clinical trials [Google translation] (Eastmoney.com) - "Haisco An announcement was made that the company's Class 1 innovative drug FTP-198 tablets has been approved for clinical trials and is intended to be used for the treatment of idiopathic pulmonary fibrosis (IPF)....FTP-198 tablets passed the Australian ethics review in January this year. Single/multiple administration, randomized, double-blind , placebo-controlled, and dose-escalation studies will be carried out in healthy people in the first quarter of 2020."

New trial • Non-US regulatory • Idiopathic Pulmonary Fibrosis

[Company] Hisco's innovative drug for idiopathic pulmonary fibrosis FTP-198 tablets was approved to enter clinical trials [Google translation] (Shenzhen Panorama Network) - "Haisco...issued an announcement stating that the company’s innovative drug FTP-198 tablets has obtained the 'Notice of Acceptance' from the National Medical Products Administration, marking that the product can apply for the indication 'Idiopathic Pulmonary Fibrosis' Clinical Trials."

Non-US regulatory • Idiopathic Pulmonary Fibrosis